Harnessing Cannabis for Patient Well-being

Realizing the full potential of the plant Cannabis and making it accessible to patients with the goal of improving their quality of life
View The Q4/H2 2022 Financial Statement

TASE:TKUN

0

-4.30%

-1.70

2025-01-23 11:50

Immediate Reports

03.03.2024

Termination of the merger agreement with Ronen Group, signing an investment agreement involving the allocation of shares and provision of services with Ronen Company.

14.02.2024

Results of Annual Meeting held on February 14, 2024

26.10.2023

Updates regarding an agreement to introduce activity to the company

18.10.2023

An update notice on behalf of the company regarding the results of the creditors' meeting and an urgent request for approval of the arrangement

27.09.2023

The unit for Medical Cannabis approved another extension, until December 31st, 2023, for the implementation of its decision

01.08.2023

Appointment of Chairman of the Board of Directors - Ronen Elad, as of August 31, 2023

01.08.2023

Ceased to serve as Chairman of the Board of Directors - Eitan Ben-Eliahu - as of 8/31/23

Results of General Meeting held on July 18, 2023

08.06.2023

In a conditional binding agreement with Ronen Elad for the introduction of Synergy activity and more against 60% of the company as well as the purchase of his securities in Plastopil

Ceased to serve as officer - CFO - Anani Liad as of 7/1/23

08.06.2023

Appointment of officer - CFO - Tony Klein from July 1, 2023

21.05.2023

It was decided to end the negotiations for a merger with BOL without proceeding to an execution of a merger agreement.

Cannbit

Investors

Follow Us

2024 Cannbit. All right reserved.
  • Privacy Policy
  • Terms of Service
  • Cookies Settings
  • Accessibility Statement